tbuckley/cabot-search huggingface dataset:
Phase II trial of oxaliplatin and gemcitabine in patients with malignant pleural or peritoneal mesothelioma
Authors: E. Hare, M. E. Hesdorrfer, J. Leinwand, L. Batista, R. N. Taub
Journal: Journal of Clinical Oncology (2008)

19086 Background: The combination of oxaliplatin (OX) and gemcitabine (GEM) is reportedly active in previously untreated pts with mesothelioma (Schutte et al., Clinical Lung Cancer 2003; 4:294). This trial was designed to confirm and further evaluate response rate and disease stability during OX and GEM treatment in pts with malignant pleural or peritoneal mesothelioma. Methods: Pts with histologically confirmed surgically incurable pleural or peritoneal mesothelioma were enrolled in this single-institution phase II trial. One prior chemotherapy regimen is allowed. Presence of at least one measurable unirradiated lesion is required. GEM 1000 mg/m2 IV over 90 minutes followed by OX 100 mg/m2 IV over 2 hours is given on day 1 of a 14-day cycle. Treatment is continued for at least 6 cycles unless unacceptable toxicity or disease progression occurs. The sequential two-stage design allows for enrollment of a total of 29 patients if 3 of 18 patients enrolled in the first stage have at least a partial response. Results: Twenty-five eligible patients have been enrolled thus far; 17 are evaluable for response. Sites of disease include pleural (10) and peritoneal (7); histologic subtypes are epithelioid (13), biphasic (3), and sarcomatoid (1). Ten patients received prior chemotherapy. A total of 132 cycles have been given with a median of 7 cycles per patient. There are four partial responses (24%) and no complete responses. Eight patients have had stable disease for at least 4 months. Two patients with partial responses received prior chemotherapy: one with pemetrexed/carboplatin and sorafenib, the other with pemetrexed/cisplatin. Three patients with stable disease had received prior pemetrexed/gemcitabine, pemetrexed/cisplatin, or pemetrexed/carboplatin. One patient with stable disease had received intraperitoneal chemotherapy with doxorubicin, cisplatin, gemcitabine, and interferon gamma B. Frequently observed toxicities included grade II fatigue, neuropathy and upper gastrointestinal dysmotility. Conclusion: This regimen of gemcitabine and oxaliplatin is modestly active in patients with malignant pleural and peritoneal mesothelioma, including those who have received prior chemotherapy. The regimen is well-tolerated. This study remains open to accrual. No significant financial relationships to disclose.
The Pregnant Woman
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Alcohol, Drug Abuse, and Mental Health Administration
Authors: J. Asher
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Caution Advised for Readers of Letters Related to Retracted Article
Authors: Khagendra Dahal, Kalgi Modi
Journal: JAMA Internal Medicine (2018)

Although the risk of ventricular arrhythmia (VA) did not show significant difference in our study, that and the prevention of ventricular remodeling process are 2 possible mechanisms by which MRA extends its benefit in survival. 5 One reason why it did not show benefit in VA could be the lack of reporting by all studies on the VA outcome.Finally, we believe that based on the available data, MRA treatment appears to be beneficial to treat patients with STEMI.However, we agree with Dr Weir that owing to the post hoc nature of analysis in the ALBATROSS study for STEMI subgroup, 2 this should be further tested and verified in future dedicated randomized clinical trials in this population of interest.
Sticks, Stones, and Hurtful Words: Relative Effects of Various Forms of Childhood Maltreatment
Authors: Martin Teicher
Journal: American Journal of Psychiatry (2006)

Objective: Childhood maltreatment is an important psychiatric risk factor. Research has focused primarily on the effects of physical abuse, sexual abuse, or witnessing domestic violence. Parental verbal aggression has received little attention as a specific form of abuse. This study was designed to delineate the impact of parental verbal aggression, witnessing domestic violence, physical abuse, and sexual abuse, by themselves and in combination, on psychiatric symptoms. Method: Symptoms and exposure ratings were collected from 554 subjects 18–22 years of age (68% female) who responded to advertisements. The Verbal Abuse Questionnaire was used to assess exposure to parental verbal aggression. Outcome measures included dissociation and symptoms of "limbic irritability," depression, anxiety, and anger-hostility. Comparisons were made by using effect sizes. Results: Verbal aggression was associated with moderate to large effects, comparable to those associated with witnessing domestic violence or nonfamilial sexual abuse and larger than those associated with familial physical abuse. Exposure to multiple forms of maltreatment had an effect size that was often greater than the component sum. Combined exposure to verbal abuse and witnessing domestic violence had a greater negative effect on some measures than exposure to familial sexual abuse. Conclusions: Parental verbal aggression was a potent form of maltreatment. Exposure to multiple forms of abuse was associated with very large effect sizes. Most maltreated children had been exposed to multiple types of abuse, and the number of different types is a critically important factor.
Health
Authors: Joseph Herman
Journal: Annals of Internal Medicine (1996)

Ad Libitum15 June 1996HealthJoseph Herman, MDJoseph Herman, MDBayit V'gan 96424 Jerusalem, IsraelSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-12-199606150-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail By way of not defining it as an absenceOf disease or disability, let us referTo what allows living in fullest measure.A cardinal feature is unobtrusiveness—No counting of stairs or hesitationOver running for a bus. Its disappearance,On the other hand, is sensed at onceAs pain in the back or a scratchy throatAnd those persistent discomforts, threateningThe knee of the inveterate walker,The music lover's ear, the surgeon's steady hand.More than mortality, what obtrudes is decline.Not thinking of the agonies he was ... Author, Article, and Disclosure InformationAffiliations: Bayit V'gan 96424 Jerusalem, IsraelCorresponding Author: Joseph Herman, MD, 42 Harav Uzziel Street, Bayit V'gan 96424, Jersusalem, Israel. Previousarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 June 1996Volume 124, Issue 12Page: 1094KeywordsDisabilitiesEmotionsKneesLower back painMortalityPharynxQuality of lifeRunning Issue Published: 15 June 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A Permanent US-Mexico Border Environmental Health Commission
Journal: JAMA (1990)

Public health officials, physicians, and politicians have long been aware of the squalid environmental conditions existing along the US-Mexico border. Some attempts have been made to improve the environmental pollution and causes of human disease, beginning as early as the 1930s with the IBWC, established in 1889. More recent agreements and legislation have called for US and Mexico cooperation by way of each nation's corresponding environmental agency (ie, the EPA and Mexico's SEDUE) and their agencies of foreign affairs (ie, the IBWC). Nevertheless, environmental monitoring and disease incidence data continue to point out that public and environmental health along the border--the result of uncontrolled air and water pollution and lack of disease vector control--is rapidly deteriorating and seriously affecting the health and future economic vitality on both sides of the border. Many prominent public health professionals and environmental organizations are concerned that the present working relationship between the United States and Mexico is not functioning well and cannot adequately cope with existing environmental conditions; for one thing, the efforts of the EPA and SEDUE are reviewed no more frequently than once a year by a staff quartered in Washington and Mexico City. Some projects to improve these conditions have been undertaken by the EPA and SEDUE and the IBWC; at present, the prospects for success do not appear promising. Consequently, these individuals and organizations have urged creation of a US-Mexico border environmental health commission. Congress did see fit last year to give responsibility for the environment to the IBWC in the form of Public Law 100-465. This law, however, does not address the full severity of environmental and public health degradation along the border; it does not address the pollution of the New River, Agua Prieta, the San Pedro River, or the Pacific Ocean, neither does it offer remedial control of hazardous waste sites, rabies, and other disease vectors. Moreover, the IBWC is only a deliberative body, not an implementing one.
THE RELATION OF THE PHYSICIAN TO THE PURITY OF DRUGS.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A diagnostic index of clinical practice
Authors: C. Cassel
Journal: JAMA (1977)

In this method of accrual of medical data by clinicians, entry and retrieval of information is facilitated by directly recording patient data in diagnostic categories according to the familiar anatomical organ system classification instead of a numerical code. The diagnostic index is kept in loose-leaf form, with tabulation of the patient's name, chart number, diagnosis, and other conditions present. Certain diagnoses are frequent enough to warrant insertion in a separate column of the page or on a separate page under the appropriate organ system. Special pages are used for diagnostic procedures, deaths, perplexing problems, and complaints, making it possible to assemble all pertinent data derived from ambulatory or hospital practice. This system allows any physician access to his own clinical experiences with minimal effort. (<i>JAMA</i>237:663-667, 1977)
Las meningitis tuberculosas del adulto
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The stability of early specialty preferences among US medical school graduates in 1983
Authors: D. Babbott
Journal: JAMA (1988)

Medical graduates in 1983 were in preclinical training when the Graduate Medical Education National Advisory Committee forecast a surplus of 70 000 physicians by 1990. Among the problems identified was the unclear role of medical schools in affecting specialty choices. To understand this role further, the current study determined the stability and evolution of specialty preferences between the time of the Medical College Admission Test and the senior year of medical school. The study included 10 321 US medical school graduates in 1983. Eighty percent changed their specialty preference during this interval, demonstrating the substantial effects that medical schools have on specialty selection. The stability of early preferences ranged from 41% to 1%. Interest in primary care specialties declined among both men and women; interest in specialty care and supporting services increased during this five-year longitudinal study. These findings parallel shifts away from primary care among US medical school graduates in 1978 and 1983. (<i>JAMA</i>1988;259:1970-1975)
Posttraumatic pleural-fluid and blood eosinophilia
Authors: U. N. Kumar
Journal: JAMA (1975)

THE FIRST case, to our knowledge, of simultaneous pleural-fluid and blood eosinophilia following chest trauma was recently reported by Beekman et al.<sup>1</sup>We report a similar case. <h3>Report of a Case</h3> A 68-year-old man fell and injured the left side of his chest. Six weeks later he was admitted to the Veterans Hospital, Wood, because of persistent chest pain unrelieved by a combination of aspirin and caffeine (Anacin). Past medical history was unremarkable except for a diagnosis of pharyngoesophageal (Zenker) diverticulum. He had no history of pleurisy or allergies and had been well before the accident. On examination he was afebrile, but there was swelling and tenderness over the lateral aspect of the left lower chest. Dullness on percussion and diminished breath sounds were noted in the left infrascapular and infra-axillary areas. Chest roentgenogram (Figure) showed blunting of the left costophrenic angle, and decubitus film confirmed the presence of
Patient online self-reporting of toxicity symptoms during chemotherapy
Authors: E. M. Basch, D. Dulko, D. Artz, K. Scher, P. Sabbatini, M. Hensley, N. Mitra, J. Speakman, M. McCabe, D. Schrag
Journal: Journal of Clinical Oncology (2005)

6025 Background: Assessing symptoms of treatment toxicity is standard practice during routine care and clinical trials. Currently, clinicians gather symptom information via complex and often inefficient mechanisms. There is growing interest in patient reported outcomes, but it remains unknown if patients can be engaged to report their own symptoms during chemotherapy, or whether practitioners will view this information as reliable towards management decisions or regulatory reporting. Methods: The NCI’s Common Terminology Criteria for Adverse Events (CTCAE) schema for 7 common symptoms was adapted into a web-based patient-reporting system, accessible from computers in outpatient clinics and from home computers. 80 outpatients with gynecologic malignancies beginning standard chemotherapy regimens were enrolled. During an 8-week observation period, participants were encouraged to login and report symptoms at each follow-up visit, or alternatively to access the system from home. Severe toxicities entered into the system (grade 3–4) triggered emails to the primary clinical team. Results: All 80 patients completed an initial login. At each subsequent appointment, most enrollees (80–85%) reported symptoms using the online system, with a mean of 3 visits per patient (range 1–6). 68/80 (85%) logged in at more than two-thirds of appointments. 60/80 (75%) logged in at least once from home, with a mean of 9 logins among home users versus 3 among non-home users. Utilization was associated with prior Internet experience (p=0.002) but not with age, cancer type, ECOG score, income, or education level. Forty-two severe toxicities entered from home prompted 7 telephone interventions and 3 new clinic visits. 96% of patients found the system useful, easy to use, and would recommend it to others. 8/9 (89%) of participating clinicians felt STAR reports reflected patients’ clinical status, and based clinical decisions on these data. Conclusion: Patients are capable of reporting symptoms experienced during chemotherapy via the web, and clinicians view these as a potentially valuable source of toxicity data. Assessment in the clinical trial setting and comparison of patient versus clinician symptom reporting will be performed in a separate study. No significant financial relationships to disclose.
Tobacco dermatitis
Authors: R. J. G. Rycroft
Journal: British Journal of Dermatology (1980)

Journal Article Tobacco dermatitis Get access R. J. G. Rycroft R. J. G. Rycroft Department of Occupational Dermatoses, St John's Hospital for Diseases of the Skin, London WC1H 7BJ Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 103, Issue 2, 1 August 1980, Pages 225–229, https://doi.org/10.1111/j.1365-2133.1980.tb06596.x Published: 01 August 1980
Monitoring resuscitation
Authors: A D Redmond
Journal: BMJ (1989)

this will generally be detectable within a few months afterwards by conventional testing for antibody."-ED,BMJ.Sudden infant death syndrome in Hong Kong SIR,-Dr Millard Bass, commenting on our paper on sudden infant death syndrome in Hong Kong,' wrongly asserted that the controls we used were unsuitable.2According to basic epidemiological principles, controls should not have the disease or condition under investigation but should be similar to cases in regard to past potential for exposure.We used one community control and one hospital control for each dead child, and we consider that neither group was subject to selection bias.The controls
Reply:
Authors: David van der Poorten, Kerry-Lee Milner, Donald J. Chisholm, Jacob George
Journal: Hepatology (2009)

We thank Prof. Dogru and colleagues for their interest in our recent article on the importance of adipocyte fatty acid binding protein (AFABP) in nonalcoholic fatty liver disease (NAFLD).1 It is now well accepted that NAFLD is the hepatic manifestation of the metabolic syndrome and as such is intimately associated with insulin resistance, visceral obesity, and dyslipidemia.2 Insulin resistance, which is a key characteristic of both conditions, has also been associated with NAFLD progression from simple steatosis to nonalcoholic steatohepatitis.3 We used the homeostasis model assessment of insulin resistance (HOMA-IR) to reflect the spectrum of insulin sensitivity. This index has been shown to correlate with the results of euglycemic-hyperinsulinemic clamp in patients without diabetes and with type 2 diabetes, including those treated with metformin and other oral hypoglycemic agents.4, 5 We were careful to exclude those taking thiazolidenediones, which have been shown to significantly affect circulating adipokine levels,6, 7 in contrast to sulfonylureas and metformin, which have not.7, 8 Type 2 diabetes eventually ensues in many subjects with increasing insulin resistance and is associated with more progressive fatty liver disease9; therefore, we decided not to exclude subjects with type 2 diabetes in our study. Although we agree it would be interesting to further subclassify subjects by glucose dysregulation status, the use of post hoc subset analysis is far less robust statistically and prone to type 2 error. We agree that metabolic variables and, in particular, measures of insulin resistance are important to consider when interpreting data on adipocytokines, which are intimately related to these factors. Indeed, our data showed the close association between both AFABP and lipocalin-2 to insulin resistance, body mass index, and waist circumference. To ensure our findings were independent of key confounders, we performed multivariate analysis for each histological endpoint in NAFLD using those factors significant on univariate analysis.1 We demonstrated that the association between AFABP and necroinflammatory and fibrotic activity is independent of abdominal obesity (the waist-hip ratio), cholesterol, high-density lipoprotein, and insulin resistance. For further clarity, as suggested by Prof. Dogru, we provide in Table 1 the relationship between AFABP and disease severity in NAFLD, directly controlled for insulin resistance and the key metabolic variables of body mass index, low-density lipoprotein, high-density lipoprotein, triglycerides, and glucose. This conclusively demonstrates that AFABP plays an important role in the pathogenesis of NAFLD independent of metabolic confounders. David van der Poorten*, Kerry-Lee Milner , Donald J. Chisholm , Jacob George*, * Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Sydney, Australia, Garvan Institute of Medical Research, University of New South Wales, Sydney, Australia.